Wound Healing Research Protocol

🔧 Recovery Support Protocol

Back to Library
🔧

Recovery Support

Wound Healing Research Protocol

Educational overview of peptides studied in wound repair and tissue regeneration

Moderate Risk ProfileintermediateLow Evidence
Research Information

This protocol is provided for educational and informational purposes only. It does not constitute medical advice, a diagnosis, a treatment plan, or a prescription.

All dose ranges, frequencies, durations, and compound selections must be determined by a licensed healthcare professional based on your individual medical history, lab results, and clinical assessment.

Lab monitoring may be required depending on the compound(s), individual health status, and duration of use. Discuss appropriate monitoring protocols with your clinician.

Do not use any peptide compound if you are pregnant, breastfeeding, a minor, or have uncontrolled medical conditions without explicit direction from your physician.

Overview

A structured educational protocol for individuals with chronic or complex wounds discussing research compound options with wound care specialists or dermatologists.

Mechanism Summary

Compounds in this category may modulate immune defense, cell migration, and angiogenesis — all critical to wound healing cascade. LL-37 has antimicrobial and pro-healing properties studied in infected wound models.

Intended Goal

Prepare for clinician discussion on wound-healing compound options

Antimicrobial / wound healing

Cathelicidin-derived; studied for antimicrobial and tissue repair properties.

Thymosin Alpha-1

View profile

Immune modulation / wound support

Immune-modulating peptide approved in some countries for specific conditions.

Protocol calculator: All compounds shown together. Set each vial size, BAC water added, and your intended dose — the draw units update instantly for every peptide in this protocol. Defaults are placeholders — adjust to your actual vials and clinician instructions.
LL-37Antimicrobial / wound healing
Draw
10
units
Conc
2500
mcg/mL
Vol
0.1
mL
Doses/vial
20
inj.
Thymosin Alpha-1Immune modulation / wound support
Draw
10
units
Conc
2500
mcg/mL
Vol
0.1
mL
Doses/vial
20
inj.

Research reference values only. Confirm all parameters with current literature and your clinician.

Who may be a candidate

  • Adults with clinician-managed chronic wounds
  • Post-surgical patients under medical care
  • Individuals with diabetic ulcer conditions under specialist management

Exclusions

  • Not for acute emergency wound care
  • Not a substitute for surgical debridement or antibiotics when clinically indicated
1

Is my wound a candidate for peptide-based therapies?

2

What is the evidence quality for this specific wound type?

3

How do we monitor for infection vs. healing?

Print or copy these questions using the "Copy Summary" button to bring to your appointment.

Legal & Compliance Notice

Verify compound status with your clinician and local regulatory authority.

The legal and regulatory status of research compounds varies by country and jurisdiction. It is the user's responsibility to understand applicable local laws before engaging with any compound.

This application does not provide personalized dosing recommendations. Users who require medical guidance should consult a qualified clinician.

Last reviewed: 2025-01-15 · Status: reviewed

Discuss with Your Clinician

Use this protocol as a research starting point. A qualified healthcare professional can review your health history, order appropriate labs, and help you determine what approach — if any — makes sense for your specific situation.

Bring this protocol to your appointmentUse the questions below as a discussion guide